Sana Biotechnology's favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a ...

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

The opening session sets the context and intent for the Inaugural Summit: USA-Saudi Biotech Alliance, outlining the strategic ...

Explore India's potential in futuristic marine and space biotechnology to enhance biomanufacturing and strengthen its ...

Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.

This session highlights the role of the King Abdullah International Medical Research Center (KAIMRC) as a core enabling ...

The average one-year price target for MAIA Biotechnology (NYSEAM:MAIA) has been revised to $10.48 / share. This is a decrease ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

Sulfolobus islandicus, an archaeal model organism, offers unique advantages for metabolic engineering and synthetic biology ...

Brennen McKenzie, MA, MSc, VMD, director of veterinary medicine at Loyal, a biotechnology company focusing on extending the ...